Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Recall Totals for 2008 Highlight Global Outsourcing and Other Risks

This article was originally published in The Gold Sheet

Executive Summary

Drug recalls surged last year as global outsourcing took toll. Inappropriate ingredients from China contributed to record 32 Class I recalls, including heparin adulterant and erectile dysfunction API. Meanwhile, U.S. facilities help drive total recalls to 426 - the highest level in seven years. Economic forces and corporate culture played contributing roles. Sage, Hydrox, Sandoz, KV, Actavis, other recall cases explored.

You may also be interested in...



B. Cepacia Hits ICUs Again, Raises Manufacturing Controls Questions

Another outbreak of B. cepacia at hospital intensive care units in multiple states implicates manufacturing and supply chain controls on aqueous non-sterile drug products, particularly for those marketed over the counter under OTC monographs.

Contamination, Mix-Ups Drive Up Drug Recall Totals for 2012

Injectables eclipsed oral solids as 2012 generated the fourth-most recalls ever. Contamination played a major role, particularly in generating several massive recalls at compounding pharmacies, while there were also contraceptive packaging snafus, problems in confronting tablet mix-ups and other issues that generated drug recalls last year.

How Pharma is Working to Change Cultures With Q10 Quality Systems

Related Content

UsernamePublicRestriction

Register

PS000337

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel